Janus Henderson Horizon Fund - Global Smaller Companies Fund on Halozyme Therapeutics, Inc.
Thesis
Halozyme performed strongly after a series of positive royalty developments. Its drug-delivery technology allows certain medicines to be administered subcutaneously rather than through intravenous infusion. The fund highlighted the resulting improvement in convenience for both patients and healthcare providers.
“improving convenience for both patients and healthcare providers.”